• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1607837-31-9 (CCT-251921)

1

Identification

CCT-251921 CCT-251921
Name CCT-251921
Formula C21H23ClN6O
MW 410.9
CAS No. 1607837-31-9
EINECS
Smiles O=C1NCCC12CCN(C3=C(Cl)C(N)=NC=C3C4=CC5=C(N(C)N=C5)C=C4)CC2
Synonyms CCT251921;CCT 251921; 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
InChI InChI=1S/C21H23ClN6O/c1-27-16-3-2-13(10-14(16)11-26-27)15-12-25-19(23)17(22)18(15)28-8-5-21(6-9-28)4-7-24-20(21)29/h2-3,10-12H,4-9H2,1H3,(H2,23,25)(H,24,29)
2

Introduction

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM.

Background Information

CCT-251921 has been found to be a CDK inhibitor that could be significant in the studies of colorectal cancer. ......by BOC Sciences
CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. ......by MedChemexpress Co., Ltd.
CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). CCT251921 showed the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer. The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. ......by MedKoo Biosciences, Inc.
A potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively; reduces STAT1 Ser727 phosphorylation, inhibits tunor growth of APC-mutant SW620 human colorectal carcinoma xenograft mode, has pharmacokinetic, and physicochemical properties. ......by ProbeChem
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000066340

Storage condition

Solubility

DMSO by CHEMSCENE, LLC
DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
CCT-251921 - No Development Reported
7

Safety Data of CCT-251921

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 1mg/USD108();5mg/USD288() USA
MedChemexpress Co., Ltd. 1mg/USD108();5mg/USD288() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Shanghai Haoyuan Chemexpress Co., Ltd. 1mg/USD108();5mg/USD288() China
10

Related Products

Other Forms of 1607837-31-9

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

CCT-251921

Tags: buy 1607837-31-9 IC50 | 1607837-31-9 price | 1607837-31-9 cost | 1607837-31-9 solubility | 1607837-31-9 purchase | 1607837-31-9 manufacturer | 1607837-31-9 research buy | 1607837-31-9 order | 1607837-31-9 MSDS | 1607837-31-9 chemical structure | 1607837-31-9 Storage condition | 1607837-31-9 molecular weight | 1607837-31-9 mw | 1607837-31-9 datasheet | 1607837-31-9 supplier | 1607837-31-9 cell line | 1607837-31-9 NMR | 1607837-31-9 MS | 1607837-31-9 IR | 1607837-31-9 solubility | 1607837-31-9 Safe information | 1607837-31-9 Qc and Spectral Information | 1607837-31-9 Clinical Information | 1607837-31-9 Clinical Trial | 1607837-31-9 Route of Synthesis | 1607837-31-9 storage condition | 1607837-31-9 diseases and conditions | 1607837-31-9 flash point | 1607837-31-9 boiling point | 1607837-31-9 melting point | 1607837-31-9 storage condition | 1607837-31-9 brand